

## Human Health Toxicity Assessment for Perfluorooctanoic Acid (PFOA)

January 2025
EPA Doc No. 822F25001

EPA published the final human health toxicity assessment for PFOA in April 2024.

A toxicity assessment summarizes the potential health effects associated with exposure to a particular chemical and identifies the dose levels at which the health effects may occur in order to calculate toxicity values.

The PFOA toxicity assessment identified adverse health effects associated with PFOA exposure using a robust systematic review process based on EPA peer-reviewed human health risk assessment methodology.

Systematic review is a structured and documented process for transparent literature review using explicit, prespecified scientific methods to identify, select, assess, and summarize the findings across relevant studies. Systematic review promotes use of the best available science and reduces bias.

The EPA followed its peer-reviewed human health risk assessment methodology and applicable guidance documents for all steps of the toxicity assessment including hazard identification, cancer classification, and toxicity value development (e.g., <u>USEPA, 2002</u>; <u>USEPA, 2012</u>; <u>USEPA, 2022</u>). The PFOA toxicity assessment incorporated <u>expert scientific recommendations</u> received from peer review and feedback from the public comment period.

## **Health Effects Identified for PFOA**

The EPA's systematic review of over <u>780 human and animal health studies</u> demonstrated PFOA exposure elicits adverse noncancer and cancer health effects (see table below). Consistent with <u>EPA's Guidelines for Carcinogen Risk Assessment</u>, the EPA concluded that PFOA is Likely to Be Carcinogenic to Humans via the oral route of exposure.

	<u></u>				
	Immune	Developmental	Cardiovascular	Liver	Cancer
Effects observed in human studies	Vaccine response in children	Infant birth     weight	↑ Serum lipids (total cholesterol and LDL) ↑ Blood pressure in adults	↑ Serum liver enzymes (ALT) indicative of liver damage in adults	Kidney and testicular cancer in adults
Effects observed in animal studies	√ Immune response	<ul> <li>✓ Pup survival</li> <li>✓ Fetal and pup body weight</li> <li>Delayed developmental timing</li> </ul>	Change in serum lipids	↑ Liver cell death and serum liver enzymes (ALT) indicative of liver damage	Testicular, pancreatic, and liver tumors

## **Toxicity Values for PFOA**

Based on the effects described above, toxicity values were calculated for PFOA – a cancer slope factor (CSF) and a reference dose (RfD) – in line with EPA peer-reviewed human health risk assessment methodology and applicable guidance documents.

- A <u>CSF</u> is an upper bound, approximating a 95% confidence limit, on the increased cancer risk from a lifetime exposure to an agent. The CSF is the change in risk per unit dose.
- A <u>RfD</u> is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human
  population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a
  lifetime. Uncertainty in the data is accounted for by including uncertainty factors in the RfD to protect public health.

	Critical Effect	Study	Population	Toxicity Value	
Cancer Slope Factor	Kidney cancer	Shearer, 2021 (supported by Viera, 2013; see Sec. 4.2.2.1)	55- to 74-year-old adults	0.0293 (ng/kg/day) <sup>-1</sup>	
Reference Dose (see page 2)	↓ Tetanus and diphtheria vaccine response	Budtz-Jørgensen, 2018	5- to 7-year-old children	3×10 <sup>−8</sup> mg/kg/day	
	se	Wikström, 2020	Infants		
	↑ Serum total cholesterol	Dong, 2019	20- to 80-year-old adults		

## Human Health Toxicity Assessment for Perfluorooctanoic Acid (PFOA)

January 2025
EPA Doc No. 822F25001

The chart below demonstrates that the PFOA exposure level expected to cause adverse noncancer effects on the immune system, development, the cardiovascular system, and the liver in humans (Point of Departure, **POD**) are similar. The chart also depicts the selected PODs with adjustments (Uncertainty Factors, **UF**) to be protective of at-risk populations and account for data gaps to derive **candidate reference doses (RfD)**. **Overall**, **or final**, **RfDs** are in orange.

Effects on the immune and cardiovascular systems, development, and the liver occur at the same or approximately the same doses of PFOA exposure in multiple studies, populations, and geographic locations, which increases confidence in the RfD.

